BCAX
NASDAQBicara Therapeutics Inc.
News25/Ratings12
News · 26 weeks81+27%
2026-03-012026-08-23
Mix3590d
- Insider19(54%)
- SEC Filings8(23%)
- Other5(14%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- SECBicara Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- ANALYSTBMO Capital Markets initiated coverage on Bicara Therapeutics with a new price targetBMO Capital Markets initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Chief Financial Officer Larson Jennifer4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 3 filed by new insider Larson Jennifer3 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- PRBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara’s 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara’s Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERPresident and COO Cohlhepp Ryan exercised 18,750 shares at a strike of $3.79 and sold $524,533 worth of shares (18,750 units at $27.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Executive Officer Mazumdar Claire exercised 10,000 shares at a strike of $3.79 and sold $279,750 worth of shares (10,000 units at $27.98) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Financial Officer Hyep Ivan sold $349,591 worth of shares (12,500 units at $27.97) as part of a pre-agreed trading plan and exercised 12,500 shares at a strike of $3.79 (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form S-8 filed by Bicara Therapeutics Inc.S-8 - Bicara Therapeutics Inc. (0002023658) (Filer)
- SECSEC Form 10-Q filed by Bicara Therapeutics Inc.10-Q - Bicara Therapeutics Inc. (0002023658) (Filer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRBicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and GrowthPresident & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors and serve as Strategic Advisor On track for substantial enrollment of pivotal FORTIFI-HN01 study by year-end, enabling topline results from interim analysis in mid-2027; initiated FORTIFI-FLEX alternate dosing study Company to host conference call and webcast today, Tuesday, August 11, 2026 at 8:30 am ET BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional
- PRBicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ETBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report second quarter 2026 financial results and business updates before the market opens on Tuesday, August 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live web
- INSIDERSEC Form 4 filed by Director Bender Jeremy4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 4 filed by Director Oliger Christy J.4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bender Jeremy3 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERSEC Form 3 filed by new insider Oliger Christy J.3 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECBicara Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
- PRBicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of DirectorsBOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporate strategy and operating experience in biotechnology to Bicara. Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations, having most rece
- SECSEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
- INSIDERChief Executive Officer Mazumdar Claire exercised 10,000 shares at a strike of $3.79 and sold $284,198 worth of shares (10,000 units at $28.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERChief Financial Officer Hyep Ivan exercised 12,500 shares at a strike of $3.79 and sold $807,672 worth of shares (28,000 units at $28.85) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 129,855 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- INSIDERPresident and COO Cohlhepp Ryan exercised 18,750 shares at a strike of $3.79 and sold $833,129 worth of shares (28,750 units at $28.98) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 181,641 units (SEC Form 4)4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
- SECSEC Form 144 filed by Bicara Therapeutics Inc.144 - Bicara Therapeutics Inc. (0002023658) (Subject)
BCAX FAQ
6 questionsWhere does BCAX stock trade?
Bicara Therapeutics Inc. (BCAX) is listed on NASDAQ.What sector and industry is BCAX in?
Bicara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bicara Therapeutics Inc. go public?
Bicara Therapeutics Inc. (BCAX) completed its IPO in 2024.What are analysts saying about BCAX?
Bicara Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform with a $3500.00 price target on 2026-08-19.What companies are similar to BCAX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BCAX side-by-side with any of them on Quantisnow.How can I track BCAX on Quantisnow?
Quantisnow aggregates Bicara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCAX to receive live email and push alerts on every new disclosure.